Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome) Latest Advances

Growth Patterns in MPS IVA and MPS IIIA: A Longitudinal Single-Center Study.

Journal: Journal of clinical medicine

Published: April 19, 2026

Long-term Natural History and Elosulfase Alfa Treatment for Mucopolysaccharidosis Type IVA: A Single-Center Study in the Czech Republic.

Journal: Research square

Published: April 03, 2026

Comprehensive analysis of hearing function in Morquio A syndrome: Implications for diagnosis and management.

Journal: Molecular genetics and metabolism

Published: February 28, 2026

Natural History of Morquio A Syndrome.

Journal: Journal of inherited metabolic disease

Published: January 30, 2026

Development of Small-Molecule Allosteric Modulators of Beta-Galactosidase (β-Gal) for the Treatment of GM1 Gangliosidosis and Morquio B.

Journal: International journal of molecular sciences

Published: January 30, 2026

AAV Gene Therapy for MPS IVA with Induction of Immune Tolerance via Oral Administration of Epitope Peptides of N-Acetylgalactosamine-6-sulfate Sulfatase.

Journal: International journal of molecular sciences

Published: January 25, 2026

Phenotypes of Elosulfase Alfa-Induced Immediate Hypersensitivity Reactions and Long-term Outcomes of Desensitization in Mucopolysaccharidosis IVA.

Journal: International archives of allergy and immunology

Published: January 14, 2026

Mucopolysaccharidosis or Skeletal Dysplasia?: Important Clinical and Radiologic Clues for Differential Diagnosis of Based on Difficult Cases.

Journal: Journal of clinical research in pediatric endocrinology

Published: December 04, 2025

Quantification of keratan sulfate in biofluids by validated HPCE-LIF: application to Morquio syndrome.

Journal: Bioanalysis

Published: December 02, 2025

Allogeneic Hematopoietic Cell Transplantation for Morquio A Syndrome: An International Retrospective Study.

Journal: Transplantation and cellular therapy

Published: November 30, 2025

Two-year follow-up of musculoskeletal outcomes and quality of life in patients with mucopolysaccharidosis type IV and VI.

Journal: Journal of pediatric endocrinology & metabolism : JPEM

Published: November 23, 2025

Long-Term Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Mucopolysaccharidosis IVA: A 10-Year Follow-Up from a Single-Center Experience in China.

Journal: Transplantation and cellular therapy

Published: November 15, 2025

Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome) Latest Advances

Find the Latest Research About Mucopolysaccharidosis Type 4 (MPS IV, Morquio Syndrome)

Growth Patterns in MPS IVA and MPS IIIA: A Longitudinal Single-Center Study.

Growth Patterns in MPS IVA and MPS IIIA: A Longitudinal Single-Center Study.

Long-term Natural History and Elosulfase Alfa Treatment for Mucopolysaccharidosis Type IVA: A Single-Center Study in the Czech Republic.

Long-term Natural History and Elosulfase Alfa Treatment for Mucopolysaccharidosis Type IVA: A Single-Center Study in the Czech Republic.

Comprehensive analysis of hearing function in Morquio A syndrome: Implications for diagnosis and management.

Comprehensive analysis of hearing function in Morquio A syndrome: Implications for diagnosis and management.

Natural History of Morquio A Syndrome.

Natural History of Morquio A Syndrome.

Development of Small-Molecule Allosteric Modulators of Beta-Galactosidase (β-Gal) for the Treatment of GM1 Gangliosidosis and Morquio B.

Development of Small-Molecule Allosteric Modulators of Beta-Galactosidase (β-Gal) for the Treatment of GM1 Gangliosidosis and Morquio B.

AAV Gene Therapy for MPS IVA with Induction of Immune Tolerance via Oral Administration of Epitope Peptides of N-Acetylgalactosamine-6-sulfate Sulfatase.

AAV Gene Therapy for MPS IVA with Induction of Immune Tolerance via Oral Administration of Epitope Peptides of N-Acetylgalactosamine-6-sulfate Sulfatase.

Phenotypes of Elosulfase Alfa-Induced Immediate Hypersensitivity Reactions and Long-term Outcomes of Desensitization in Mucopolysaccharidosis IVA.

Phenotypes of Elosulfase Alfa-Induced Immediate Hypersensitivity Reactions and Long-term Outcomes of Desensitization in Mucopolysaccharidosis IVA.

Mucopolysaccharidosis or Skeletal Dysplasia?: Important Clinical and Radiologic Clues for Differential Diagnosis of Based on Difficult Cases.

Mucopolysaccharidosis or Skeletal Dysplasia?: Important Clinical and Radiologic Clues for Differential Diagnosis of Based on Difficult Cases.

Quantification of keratan sulfate in biofluids by validated HPCE-LIF: application to Morquio syndrome.

Quantification of keratan sulfate in biofluids by validated HPCE-LIF: application to Morquio syndrome.

Allogeneic Hematopoietic Cell Transplantation for Morquio A Syndrome: An International Retrospective Study.

Allogeneic Hematopoietic Cell Transplantation for Morquio A Syndrome: An International Retrospective Study.

Two-year follow-up of musculoskeletal outcomes and quality of life in patients with mucopolysaccharidosis type IV and VI.

Two-year follow-up of musculoskeletal outcomes and quality of life in patients with mucopolysaccharidosis type IV and VI.

Long-Term Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Mucopolysaccharidosis IVA: A 10-Year Follow-Up from a Single-Center Experience in China.

Long-Term Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Mucopolysaccharidosis IVA: A 10-Year Follow-Up from a Single-Center Experience in China.